I don’t know anything more than anyone else. I just put 2 and 2 together from a different perspective. I believe MHRA approval is a lock, and I believe it because I see the evidence. I also believe FDA approval is a lock, and I believe it because of Pazdur’s paper basically using NWBO’s SAP as the guideline for outside comparators for serious disease as well as his more recent paper regarding accelerated approval. I don’t believe in coincidence. I also believe it’s probable the paper has been accepted and awaiting a publication date. I believe this because the timing seems appropriate and I believe a journal such as NEJM would want this paper coming from them and that it will coincide with Dr. Liau’s presentation as SNO.
So the “wheeling and dealing” in my perspective would be raising capital to quickly expand manufacturing both in the UK and in the US and that’s why the recent S3 filing with much more stock than they had registered. So now you have preferred shares for a big institution to partner and regular shares to sell to large investors who’ve supported the company over the past several years waiting for the big reveal. We create new operations in the US and build more capacity at Sawston, and start new pediatric trials, Direct trials, and trials to expand indications to all solid tumors. MHRA approves as does Canada, followed 4-6 months later by FDA and the BOOM you hear resonates around the world. EMA follows, and the revenues come rolling in.
Yeah, I’m a dreamer. But so is Linda Powers and Les Goldman. I invest in my dreams
AI
Market Data 
Markets 
